Fierce Pharma

Riding high on its Daiichi Sankyo-partnered ADC Enhertu—and banking on an approval for its next ADC contender datopotamab durextecan this winter—AstraZeneca is placing a big bet on the cancer-fighting technology as it blueprints a massive manufacturing investment in Asia.

Sanofi and Regeneron’s Dupixent appears set up for a key FDA approval this summer for COPD. But a second biologic treatment could be on its heels in the indication.

Once again, the dominant players were the sellers of GLP-1 diabetes and obesity drugs. While Novo Nordisk dropped out of the top spot with its 22% year-over-year revenue increase, Eli Lilly took over as No. 1 thanks to its 28% quarterly boost.

Sanofi, Pfizer and AstraZeneca lead a group of several biopharma companies that are bolstering their operations in France.

Before now, the healthcare professional/pharmaceutical relationship was a strictly face-to-face interaction that built a multi billion-dollar industry. Today, the once valuable in-person meeting has become digital, enabling brands to reach physicians in new, more reliable, and more effective ways. Download the whitepaper to learn how Direct Messaging and Mobile can significantly enhance your communications and marketing efforts. #sponsored

After years of missteps in developing and commercializing its coronavirus shot, Novavax is turning to one of the biopharma industry’s most experienced vaccine companies to help salvage its COVID efforts: Sanofi.

In response to rapidly declining profits and the downfall of ADHD drug Vyvanse, Takeda is planning to throw nearly $900 million toward a company-wide restructuring campaign.

In about a year after launching a revamp strategy under CEO Richard Francis, Teva Pharmaceuticals has managed to return its generics business to growth, secure approvals for a pair of high-profile biosimilars and chart market gains with its star-branded treatment, Austedo, in Huntington’s disease.

Even after consumer outfit Kenvue split from Johnson & Johnson one year ago, the company has been performing certain services for the pharma and medtech giant as part of a transition process. Now, as that arrangement comes to a close, Kenvue is plotting hundreds of layoffs. 

With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward.